PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells

Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision...

Full description

Saved in:
Bibliographic Details
Main Authors: Cheng, Haiying, Zhang, Zhenfeng, Borczuk, Alain, Powell, Charles A., Balajee, Adayabalam S., Lieberman, Howard B., Halmos, Balazs
Format: Artigo
Language:Inglês
Published: Oxford University Press 2013
Subjects:
Original Manuscript
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616665/
https://ncbi.nlm.nih.gov/pubmed/23275151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgs393
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items